Need help finding what you are looking for?
Contact Us
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1629147
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1629147
Particle Therapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)
PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global particle therapy market is projected to grow from $1,008.9 million in 2024 to $1,634.4 million by 2030, registering a compound annual growth rate (CAGR) of 8.4%. This growth is primarily driven by the increasing prevalence of cancer and the rising adoption of particle therapy as a precise and non-invasive treatment option. Advancements in technology, such as the integration of artificial intelligence (AI) and machine learning (ML) in treatment planning, are further enhancing the precision and effectiveness of particle therapy. Additionally, the establishment of more particle therapy centers and supportive government initiatives are bolstering market expansion.
Key Insights
The rising global incidence of cancer is driving demand for particle therapy, which minimizes damage to healthy tissues while effectively targeting tumors.
Technological advancements, including the integration of AI and ML, are improving treatment accuracy and operational efficiency in particle therapy.
The increasing number of particle therapy centers worldwide is enhancing accessibility to this advanced treatment, contributing to market growth.
Government policies and funding aimed at improving cancer treatment infrastructure are supporting the adoption of particle therapy in healthcare facilities.
Patients prefer particle therapy for its non-invasive nature and reduced side effects compared to conventional cancer treatments.
Research and development efforts are focused on improving particle therapy techniques and expanding their clinical applications, opening new growth opportunities.
High equipment and treatment costs may pose challenges to the widespread adoption of particle therapy, particularly in developing regions.
The market is highly competitive, with companies investing in innovations and strategic collaborations to strengthen their position.
Europe holds a significant market share due to the presence of advanced healthcare infrastructure and numerous particle therapy centers.
The development of compact and cost-effective particle therapy systems, along with the growing focus on personalized medicine, is expected to drive future market growth.
Product Code: 12383
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by offering
- 1.4.3. Market size breakdown, by system
- 1.4.4. Market size breakdown, by cancer type
- 1.4.5. Market size breakdown, by application
- 1.4.6. Market size breakdown, by end user
- 1.4.7. Market size breakdown, by region
- 1.4.8. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Type (2019-2030)
- 6.3. Market Revenue, by Offering (2019-2030)
- 6.4. Market Revenue, by System (2019-2030)
- 6.5. Market Revenue, by Cancer Type (2019-2030)
- 6.6. Market Revenue, by Application (2019-2030)
- 6.7. Market Revenue, by End User (2019-2030)
- 6.8. Market Revenue, by Region (2019-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Type (2019-2030)
- 7.3. Market Revenue, by Offering (2019-2030)
- 7.4. Market Revenue, by System (2019-2030)
- 7.5. Market Revenue, by Cancer Type (2019-2030)
- 7.6. Market Revenue, by Application (2019-2030)
- 7.7. Market Revenue, by End User (2019-2030)
- 7.8. Market Revenue, by Country (2019-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Type (2019-2030)
- 8.3. Market Revenue, by Offering (2019-2030)
- 8.4. Market Revenue, by System (2019-2030)
- 8.5. Market Revenue, by Cancer Type (2019-2030)
- 8.6. Market Revenue, by Application (2019-2030)
- 8.7. Market Revenue, by End User (2019-2030)
- 8.8. Market Revenue, by Country (2019-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Type (2019-2030)
- 9.3. Market Revenue, by Offering (2019-2030)
- 9.4. Market Revenue, by System (2019-2030)
- 9.5. Market Revenue, by Cancer Type (2019-2030)
- 9.6. Market Revenue, by Application (2019-2030)
- 9.7. Market Revenue, by End User (2019-2030)
- 9.8. Market Revenue, by Country (2019-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Type (2019-2030)
- 10.3. Market Revenue, by Offering (2019-2030)
- 10.4. Market Revenue, by System (2019-2030)
- 10.5. Market Revenue, by Cancer Type (2019-2030)
- 10.6. Market Revenue, by Application (2019-2030)
- 10.7. Market Revenue, by End User (2019-2030)
- 10.8. Market Revenue, by Country (2019-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Type (2019-2030)
- 11.3. Market Revenue, by Offering (2019-2030)
- 11.4. Market Revenue, by System (2019-2030)
- 11.5. Market Revenue, by Cancer Type (2019-2030)
- 11.6. Market Revenue, by Application (2019-2030)
- 11.7. Market Revenue, by End User (2019-2030)
- 11.8. Market Revenue, by Country (2019-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Type (2019-2030)
- 12.3. Market Revenue, by Offering (2019-2030)
- 12.4. Market Revenue, by System (2019-2030)
- 12.5. Market Revenue, by Cancer Type (2019-2030)
- 12.6. Market Revenue, by Application (2019-2030)
- 12.7. Market Revenue, by End User (2019-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Type (2019-2030)
- 13.3. Market Revenue, by Offering (2019-2030)
- 13.4. Market Revenue, by System (2019-2030)
- 13.5. Market Revenue, by Cancer Type (2019-2030)
- 13.6. Market Revenue, by Application (2019-2030)
- 13.7. Market Revenue, by End User (2019-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Type (2019-2030)
- 14.3. Market Revenue, by Offering (2019-2030)
- 14.4. Market Revenue, by System (2019-2030)
- 14.5. Market Revenue, by Cancer Type (2019-2030)
- 14.6. Market Revenue, by Application (2019-2030)
- 14.7. Market Revenue, by End User (2019-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Type (2019-2030)
- 15.3. Market Revenue, by Offering (2019-2030)
- 15.4. Market Revenue, by System (2019-2030)
- 15.5. Market Revenue, by Cancer Type (2019-2030)
- 15.6. Market Revenue, by Application (2019-2030)
- 15.7. Market Revenue, by End User (2019-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Type (2019-2030)
- 16.3. Market Revenue, by Offering (2019-2030)
- 16.4. Market Revenue, by System (2019-2030)
- 16.5. Market Revenue, by Cancer Type (2019-2030)
- 16.6. Market Revenue, by Application (2019-2030)
- 16.7. Market Revenue, by End User (2019-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Type (2019-2030)
- 17.3. Market Revenue, by Offering (2019-2030)
- 17.4. Market Revenue, by System (2019-2030)
- 17.5. Market Revenue, by Cancer Type (2019-2030)
- 17.6. Market Revenue, by Application (2019-2030)
- 17.7. Market Revenue, by End User (2019-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Type (2019-2030)
- 18.3. Market Revenue, by Offering (2019-2030)
- 18.4. Market Revenue, by System (2019-2030)
- 18.5. Market Revenue, by Cancer Type (2019-2030)
- 18.6. Market Revenue, by Application (2019-2030)
- 18.7. Market Revenue, by End User (2019-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Type (2019-2030)
- 19.3. Market Revenue, by Offering (2019-2030)
- 19.4. Market Revenue, by System (2019-2030)
- 19.5. Market Revenue, by Cancer Type (2019-2030)
- 19.6. Market Revenue, by Application (2019-2030)
- 19.7. Market Revenue, by End User (2019-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Type (2019-2030)
- 20.3. Market Revenue, by Offering (2019-2030)
- 20.4. Market Revenue, by System (2019-2030)
- 20.5. Market Revenue, by Cancer Type (2019-2030)
- 20.6. Market Revenue, by Application (2019-2030)
- 20.7. Market Revenue, by End User (2019-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Type (2019-2030)
- 21.3. Market Revenue, by Offering (2019-2030)
- 21.4. Market Revenue, by System (2019-2030)
- 21.5. Market Revenue, by Cancer Type (2019-2030)
- 21.6. Market Revenue, by Application (2019-2030)
- 21.7. Market Revenue, by End User (2019-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Type (2019-2030)
- 22.3. Market Revenue, by Offering (2019-2030)
- 22.4. Market Revenue, by System (2019-2030)
- 22.5. Market Revenue, by Cancer Type (2019-2030)
- 22.6. Market Revenue, by Application (2019-2030)
- 22.7. Market Revenue, by End User (2019-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Type (2019-2030)
- 23.3. Market Revenue, by Offering (2019-2030)
- 23.4. Market Revenue, by System (2019-2030)
- 23.5. Market Revenue, by Cancer Type (2019-2030)
- 23.6. Market Revenue, by Application (2019-2030)
- 23.7. Market Revenue, by End User (2019-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Type (2019-2030)
- 24.3. Market Revenue, by Offering (2019-2030)
- 24.4. Market Revenue, by System (2019-2030)
- 24.5. Market Revenue, by Cancer Type (2019-2030)
- 24.6. Market Revenue, by Application (2019-2030)
- 24.7. Market Revenue, by End User (2019-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Type (2019-2030)
- 25.3. Market Revenue, by Offering (2019-2030)
- 25.4. Market Revenue, by System (2019-2030)
- 25.5. Market Revenue, by Cancer Type (2019-2030)
- 25.6. Market Revenue, by Application (2019-2030)
- 25.7. Market Revenue, by End User (2019-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Type (2019-2030)
- 26.3. Market Revenue, by Offering (2019-2030)
- 26.4. Market Revenue, by System (2019-2030)
- 26.5. Market Revenue, by Cancer Type (2019-2030)
- 26.6. Market Revenue, by Application (2019-2030)
- 26.7. Market Revenue, by End User (2019-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Type (2019-2030)
- 27.3. Market Revenue, by Offering (2019-2030)
- 27.4. Market Revenue, by System (2019-2030)
- 27.5. Market Revenue, by Cancer Type (2019-2030)
- 27.6. Market Revenue, by Application (2019-2030)
- 27.7. Market Revenue, by End User (2019-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Type (2019-2030)
- 28.3. Market Revenue, by Offering (2019-2030)
- 28.4. Market Revenue, by System (2019-2030)
- 28.5. Market Revenue, by Cancer Type (2019-2030)
- 28.6. Market Revenue, by Application (2019-2030)
- 28.7. Market Revenue, by End User (2019-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Mevion Medical Systems Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Optivus Proton Therapy Inc.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. ProTom International Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Provision Healthcare
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Elekta AB
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Toshiba Medical Systems Corporation
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Varian Medical Systems Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Hitachi Ltd.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Advanced Oncotherapy plc
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.